Corporate Profile
To become a world leader in the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 and to leverage our expertise in liver diseases to create optimized therapeutics for NASH.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Events
Jan 11, 2021 at 3:40 PM EST
Dec 1 - Dec 3, 2020